CAR-T cell therapy (National University Hospital Singapore)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCAR-T cell therapy (National University Hospital Singapore)

Drug Alias NameALaCART

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsBrain DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational University Hospital (Singapore)

China Registration ClassN/A

Develop Information

Active CompaniesNational University Hospital (Singapore)

Inactive CompaniesN/A

Active IndicationsBrain DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphoid

Inactive IndicationsN/A

Other Information

ATC CodeN/A